Glaukos Corporation (NYSE:GKOS) Stock Price & Quote Analysis

GKOS Stock Overview

Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases.

GKOS fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	1/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Rewards

Revenue is forecast to grow 12.1% per year

Risk Analysis

Currently unprofitable and not forecast to become profitable over the next 3 years

My Notes

New

Notes are coming soon

Glaukos Corporation Competitors

AtriCure

NasdaqGM:ATRC

US$2.0b

Omnicell

NasdaqGS:OMCL

US$2.6b

Integer Holdings

NYSE:ITGR

US$2.4b

NuVasive

NasdaqGS:NUVA

US$2.4b

Price History & Performance

Summary of all time highs, changes and price drops for Glaukos
Historical stock prices
Current Share Price	US$48.04
52 Week High	US$64.49
52 Week Low	US$33.33
Beta	1.2
1 Month Change	9.98%
3 Month Change	-14.32%
1 Year Change	-6.88%
3 Year Change	-14.60%
5 Year Change	60.62%
Change since IPO	53.88%

Glaukos sees positive data from mid-stage trial of dry eye treatment

Jan 10

Glaukos: Show Me The Money

Nov 10

Recent updates

Here's Why Glaukos Corporation's (NYSE:GKOS) CEO Compensation Is The Least Of Shareholders' Concerns

May 27

Is Glaukos (NYSE:GKOS) Weighed On By Its Debt Load?

Apr 30

Calculating The Intrinsic Value Of Glaukos Corporation (NYSE:GKOS)

Mar 30

At US$89.02, Is It Time To Put Glaukos Corporation (NYSE:GKOS) On Your Watch List?

Mar 04

Glaukos' (NYSE:GKOS) Wonderful 524% Share Price Increase Shows How Capitalism Can Build Wealth

Feb 06

Shareholder Returns

	GKOS	US Medical Equipment	US Market
7D	-1.0%	-0.2%	2.8%
1Y	-6.9%	-9.7%	-9.2%

Return vs Industry: GKOS exceeded the US Medical Equipment industry which returned -9.7% over the past year.

Return vs Market: GKOS exceeded the US Market which returned -9.2% over the past year.

Price Volatility

Is GKOS's price volatile compared to industry and market?
GKOS volatility
GKOS Average Weekly Movement	5.7%
Medical Equipment Industry Average Movement	8.8%
Market Average Movement	6.9%
10% most volatile stocks in US Market	17.3%
10% least volatile stocks in US Market	2.8%

Stable Share Price: GKOS is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: GKOS's weekly volatility (6%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1998	727	Tom Burns	https://www.glaukos.com

Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company’s product pipeline includes iStent Infinite, a three stents product that is designed for use as a standalone procedure in patients with refractory glaucoma; and iDose TR, a targeted injectable implant based on its micro-scale device-platform that is designed to deliver therapeutic levels of medication.

Glaukos Corporation Fundamentals Summary

How do Glaukos's earnings and revenue compare to its market cap?
GKOS fundamental statistics
Market Cap	US$2.29b
Earnings (TTM)	-US$89.61m
Revenue (TTM)	US$284.88m

8.0x

P/S Ratio

-25.6x

P/E Ratio

Is GKOS overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
GKOS income statement (TTM)
Revenue	US$284.88m
Cost of Revenue	US$68.62m
Gross Profit	US$216.25m
Other Expenses	US$305.86m
Earnings	-US$89.61m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)	-1.88
Gross Margin	75.91%
Net Profit Margin	-31.45%
Debt/Equity Ratio	51.2%

How did GKOS perform over the long term?

See historical performance and comparison

GKOS Stock Overview

Rewards

Risk Analysis

Glaukos Corporation Competitors

NasdaqGM:ATRC

US$2.0b

NasdaqGS:OMCL

US$2.6b

NYSE:ITGR

US$2.4b

NasdaqGS:NUVA

US$2.4b

Price History & Performance

Recent News & Updates

Glaukos Corporation Announces Positive Results for iDose TR Exchange Trial, Highlighting Favorable Safety and Tolerability

Glaukos Corporation Announces Positive Clinical Updates for Several Corneal Health Pipeline Programs

Glaukos sees positive data from mid-stage trial of dry eye treatment

Glaukos: Show Me The Money

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Glaukos Corporation Provides Revenue Guidance for the Year 2022

Recent updates

Glaukos Corporation Announces Positive Results for iDose TR Exchange Trial, Highlighting Favorable Safety and Tolerability

Glaukos Corporation Announces Positive Clinical Updates for Several Corneal Health Pipeline Programs

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Glaukos Corporation Provides Revenue Guidance for the Year 2022

Does Glaukos (NYSE:GKOS) Have A Healthy Balance Sheet?

Glaukos Corporation to Report Q3, 2022 Results on Nov 02, 2022

Glaukos Corporation Announces Positive Topline Outcomes for Both Phase 3 Pivotal Trials of iDose TR, Achieving Primary Efficacy Endpoints and Demonstrating Favorable Tolerability and Safety Profiles

Consensus forecasts updated

Price target increased to US$59.00

Glaukos Corporation Revises Sales Guidance for the Year 2022

Glaukos Corporation to Report Q2, 2022 Results on Aug 03, 2022

Is Glaukos (NYSE:GKOS) Using Debt Sensibly?

Consensus estimates of losses per share improve by 21%

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Glaukos Corporation Updates Sales Guidance for the Year 2022

Glaukos Corporation, Annual General Meeting, Jun 02, 2022

Glaukos Corporation to Report Q1, 2022 Results on May 04, 2022

Does Glaukos (NYSE:GKOS) Have A Healthy Balance Sheet?

Consensus forecasts updated

Glaukos Corporation Provides Sales Guidance for the Year 2022

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Glaukos Corporation Announces Executive Changes

Glaukos Corporation to Report Q4, 2021 Results on Feb 22, 2022

Glaukos Corporation Announces First Patient Enrolled in Phase 2 Clinical Trial for Presbyopia

Glaukos Corporation Receives 510(K) Clearance from the U.S. Food and Drug Administration for the iPRIME

Is Glaukos (NYSE:GKOS) Using Debt Sensibly?

Price target increased to US$54.38

Third quarter 2021 earnings released: EPS US$0.13 (vs US$0.35 loss in 3Q 2020)

Glaukos Announces Submission of Supplemental Pre-Market Approval Application for iStent infinite

Is Glaukos (NYSE:GKOS) Weighed On By Its Debt Load?

CEO, President & Director exercised options to buy US$14m worth of stock.

Second quarter 2021 earnings released: US$0.38 loss per share (vs US$0.90 loss in 2Q 2020)

Consensus forecasts updated

Glaukos Corporation Provides Sales Guidance for the Year 2021

Consensus forecasts updated

Price target decreased to US$78.30

When Should You Buy Glaukos Corporation (NYSE:GKOS)?

Glaukos Corporation announces completion of patient enrollment for iDose TR

Glaukos Corporation Announces Australia’s TGA Regulatory Approval for PRESERFLO™ MicroShunt

Here's Why Glaukos Corporation's (NYSE:GKOS) CEO Compensation Is The Least Of Shareholders' Concerns

Key Executive exercised options and sold US$827k worth of stock

First quarter 2021 earnings released: US$0.36 loss per share (vs US$1.24 loss in 1Q 2020)

Glaukos Corporation Provides Sales Guidance for Second Quarter Ended June 30, 2021

Is Glaukos (NYSE:GKOS) Weighed On By Its Debt Load?

Calculating The Intrinsic Value Of Glaukos Corporation (NYSE:GKOS)

Key Executive exercised options and sold US$244k worth of stock

Analysts update estimates

At US$89.02, Is It Time To Put Glaukos Corporation (NYSE:GKOS) On Your Watch List?

Glaukos Corporation Announces Board Appointments

New 90-day high: US$97.42

Full year 2020 earnings released: US$2.71 loss per share (vs US$0.41 profit in FY 2019)

Revenue beats expectations

Glaukos Corporation Announces Positive Phase 3 Trial Results for Ilink™ Epi-On Investigational Therapy That Met the Primary Efficacy Endpoint

Key Executive exercised options and sold US$795k worth of stock

Glaukos' (NYSE:GKOS) Wonderful 524% Share Price Increase Shows How Capitalism Can Build Wealth

Chief Operating Officer exercised options and sold US$4.3m worth of stock

Price target raised to US$73.30

New 90-day high: US$95.84

Glaukos Corporation to Report Q4, 2020 Results on Feb 25, 2021